ASH annual meeting 2014
SCIENTIFIC CONGRESS - ERYTECH Pharma participates in ASH annual meeting 2014 from December 6 to 9 in San Francisco, CA, USA. The post ASH annual meeting 2014 appeared first on Erytech Pharma.
View ArticleERYTECH enters EnterNext© PEA-PME 150 index
ERYTECH enters EnterNext© PEA-PME 150 index The post ERYTECH enters EnterNext© PEA-PME 150 index appeared first on Erytech Pharma.
View ArticleERYTECH to report positive initial results on the use of GRASPA® in ALL...
ERYTECH to report positive initial results on the use of GRASPA® in ALL patients allergic to E. Coli and Erwinia derived asparaginases at ASH The post ERYTECH to report positive initial results on the...
View ArticleERYTECH to present at Jefferies Global Healthcare Conference
Lyon, France, November 14, 2014 - ERYTECH (Euronext Paris: FR0011471135 – ERYP), the French biopharmaceutical company that develops innovative ‘tumor starvation’ treatments for acute leukemia and other...
View ArticleERYTECH Pharma prize winner of Deloitte Technology Fast 50 2014
ERYTECH Pharma prize winner of Deloitte Technology Fast 50 2014 Rhône-Alpes Bourgogne Auvergne The post ERYTECH Pharma prize winner of Deloitte Technology Fast 50 2014 appeared first on Erytech Pharma.
View ArticleERYTECH reports additional positive Phase III results from clinical study...
ERYTECH reports additional positive Phase III results from the pivotal study with ERY-ASP/GRASPA® in Acute Lymphoblastic Leukemia The post ERYTECH reports additional positive Phase III results from...
View ArticleERYTECH announces management change
ERYTECH today announced that Pierre-Olivier Goineau will be leaving the company to pursue other interests. The post ERYTECH announces management change appeared first on Erytech Pharma.
View ArticleERYTECH at JP Morgan
ERYTECH is attending JP Morgan in San Francisco, Ca, USA from January 12 to 13, 2015 The post ERYTECH at JP Morgan appeared first on Erytech Pharma.
View ArticleERYTECH announces ADR Level 1 listing in the US
ERYTECH today announced the launch of a sponsored American Depository Receipt (ADR) Level 1 listing in the United States in order to support the expansion of the Company's US investor base. The post...
View Article17th Annual BIO CEO INVESTOR Conference
Finance - ERYTECH Pharma participates on February 9-10, 2015 to BIO CEO INVESTOR Conference taking place in New York City, NY, USA The post 17th Annual BIO CEO INVESTOR Conference appeared first on...
View ArticleTECHNICIEN(NE) DE LABORATOIRE
TECHNICIEN(NE) DE LABORATOIRE Sous la supervision du chef de projets R&D, vos missions seront de Participer au développement préclinique de nouveaux produits développés sur la plateforme de...
View ArticleACUTE LEUKEMIA XV – Munich
SCIENTIFIC CONGRESS - ERYTECH Pharma attends Acute Leukemia XV from February 22 to 25, 2015 in Munich, Germany The post ACUTE LEUKEMIA XV – Munich appeared first on Erytech Pharma.
View Article3rd ANNUAL Sachs Cancer Bio Partnering & Investment Forum
FINANCE - ERYTECH Pharma attends 3rd ANNUAL Sachs Cancer Bio Partnering & Investment Forum on February 23rd, 2015, New York City, NY, USA The post 3rd ANNUAL Sachs Cancer Bio Partnering &...
View ArticleBIO Europe Spring 2015 – PARIS March 9-11
PARTNERING - ERYTECH Pharma participates in BIO Europe Spring 2015 which takes place in Paris, France from March 9 to 11, 2015 The post BIO Europe Spring 2015 – PARIS March 9-11 appeared first on...
View ArticleAACR Annual Meeting 2015
ERYTECH Pharma is presenting 3 posters at 'American Association for Cancer Research (AACR) Annual Meeting from April 18 to 22, 2015 in Philadelphie, PA, USA. The post AACR Annual Meeting 2015 appeared...
View ArticleCITIM 2015 congress
ERYTECH Pharma makes an oral presentation on April 30 Session 12 from 2:30 pm to 3:30 pm at CITIM 2015 congress which takes place from April 27 to 30 in Ljubljana, Slovenia. The post CITIM 2015...
View ArticleERYTECH strengthens its intellectual property position in the US
ERYTECH Pharma announces the strengthening of its intellectual property portfolio in the United States with the granting of a new patent and the further extension of the patent term of its core process...
View ArticleERYTECH receives the EnterNext Tech 40 Label
ERYTECH Pharma has received the EnterNext Tech 40 Label and announces its inclusion in the Tech 40 index The post ERYTECH receives the EnterNext Tech 40 Label appeared first on Erytech Pharma.
View ArticleERYTECH announces positive DSMB annual review of its Expanded Access Program...
ERYTECH Pharma announces that an independent Data and Safety Monitoring Board (DSMB) completed its first safety assessment of the company’s Expanded Access Program (EAP) in Acute Lymphoblastic Leukemia...
View ArticleERYTECH reports financial highlights for Q1 2015
ERYTECH Pharma reports cash balance and revenues for the first quarter of 2015 The post ERYTECH reports financial highlights for Q1 2015 appeared first on Erytech Pharma.
View Article